Issue Highlights

Original Research Articles
  • Risk of second primary malignancies among patients with carcinoid of the lung

    Wieneke A. Buikhuisen, Laurie C. Steinbusch, Liudmila L. Kodach, Margot E.T. Tesselaar, Ronald A.M. Damhuis
    Lung Cancer, Vol. 151
  • Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer

    Youngjoo Lee, Jungnam Joo, You Jin Lee, Eun Kyung Lee, Sohyun Park, Tae-Sung Kim, Soo-Hyun Lee, So Young Kim, Gyung-Ah Wie, Minjoung Park, Mi-Jung Kim, Jin Soo Lee, Ji-Youn Han
    Lung Cancer, Vol. 151
  • Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)

    Corinne Faivre-Finn, David R. Spigel, Suresh Senan, Corey Langer, Bradford A. Perez, Mustafa Özgüroğlu, Davey Daniel, Augusto Villegas, David Vicente, Rina Hui, Shuji Murakami, Luis Paz-Ares, Helen Broadhurst, Catherine Wadsworth, Phillip A. Dennis, Scott J. Antonia
    Lung Cancer, Vol. 151
    Open Access
      • Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: first clinical experience

        Florian Eichhorn, Laura V. Klotz, Mark Kriegsmann, Helge Bischoff, Marc A. Schneider, Thomas Muley, Katharina Kriegsmann, Uwe Haberkorn, Claus Peter Heussel, Rajkumar Savai, Inka Zoernig, Dirk Jaeger, Michael Thomas, Hans Hoffmann, Hauke Winter, Martin E. Eichhorn
        Publication stage: In Press Journal Pre-Proof
        Published online: January 20, 2021
      • Erratum to “Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors” [Lung Cancer 150 (2020) 76–82]

        Xiangling Chu, Jing Zhao, Juan Zhou, Fei Zhou, Tao Jiang, Sen Jiang, Xiwen Sun, Xiaofang You, Fengying Wu, Shengxiang Ren, Caicun Zhou, Chunxia Su
        Publication stage: In Press Corrected Proof
        Published online: January 15, 2021
      • A reply to “Cardiac dysfunction due to Osimertinib”

        Kei Kunimasa
        Publication stage: In Press Corrected Proof
        Published online: January 14, 2021
      • Delta-like 1 homolog (DLK1) as a possible therapeutic target and its application to radioimmunotherapy using 125I-labelled anti-DLK1 antibody in lung cancer models (HOT1801 and FIGHT004)

        Hironori Takagi, Songji Zhao, Satoshi Muto, Hiroshi Yokouchi, Hiroshi Nishihara, Toshiyuki Harada, Hikaru Yamaguchi, Hayato Mine, Masayuki Watanabe, Yuki Ozaki, Takuya Inoue, Takumi Yamaura, Mitsuro Fukuhara, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Yutaka Shio, Ryuzo Kanno, Miho Aoki, Chengbo Tan, Saki Shimoyama, Shigeo Yamazaki, Hajime Kikuchi, Jun Sakakibara-Konishi, Satoshi Oizumi, Masao Harada, Kenji Akie, Fumiko Sugaya, Yuka Fujita, Kei Takamura, Tetsuya Kojima, Osamu Honjo, Yoshinori Minami, Masaharu Nishimura, Hirotoshi Dosaka-Akita, Koji Nakamura, Akihiro Inano, Hiroshi Isobe, Hiroyuki Suzuki
        Publication stage: In Press Journal Pre-Proof
        Published online: January 13, 2021
        Open Access
      • Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial

        Sharyn I. Katz, Leonid Roshkovan, Ian Berger, Joseph S. Friedberg, Evan W. Alley, Charles B. Simone II, Andrew R. Haas, Keith A. Cengel, Daniel H. Sterman, Steve M. Albelda
        Publication stage: In Press Journal Pre-Proof
        Published online: January 13, 2021

    2020 Cited articles

    ILCCO

    The International Lung Cancer Consortium (ILCCO) is an international group of lung cancer researchers, established in 2004 with the aim of sharing comparable data from ongoing lung cancer case-control and cohort studies. Questionnaire data from a total of 26000 case-control pairs, and the biological samples from the majority of the subjects would be available. These studies are from different geographical areas and ethnicities. The overall objectives are to achieve greater power, especially for subgroup analyses, reduce duplication of research effort, replicate novel findings, and afford substantial cost savings through large collaborative efforts.

    etop

    European Thoracic Oncology Platform

    ETOP comprises 30 of the leading European Thoracic Oncology clinical and translational research groups and associations.

    The European Thoracic Oncology Platform (ETOP) is a foundation with the purpose to promote exchange and research in the field of thoracic malignancies in Europe. It is a non-profit organisation with its legal seat in Bern, Switzerland.

    The specific aims of ETOP are as follows:

    • To serve as a meeting platform for European study groups and institutions dealing with thoracic malignancies
    • To foster intergroup studies among, but not exclusively, European study groups and institutions
    • To sponsor and/or perform own studies
    • To foster scientific exchange on laboratory and clinical issues among interested parties and beyond
    • To provide knowledge to partners in the field
    BTOG

    British Thoracic Oncology Group (BTOG) was established in 2002 and aims to improve the care of patients with thoracic malignancies through multidisciplinary education, developing and advising on guidelines for patient care and to facilitate and nurture clinical trial ideas into full protocols. BTOG represents all the disciplines involved in the care of lung cancer and mesothelioma throughout the UK. All individuals involved in any aspect of lung cancer or mesothelioma research, care or treatment are eligible to become members of BTOG. BTOG's annual conference is held in January every year.

    Current Issue

    January 2021
    Volume 151

    List of Issues

    Supports Open Access

    Learn more about open access options.

    Journal Metrics

    2019 Impact Factor: 4.702
    View More on Journal Insights

    © 2019 Journal Citation Report
    ® Clarivate Analytics, 2020

    About Lung Cancer

    Original research articles, early reports, review articles, commentaries and editorials covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are all welcome. Letters to the journals are also welcomed although authors should be aware that the majority will be published online only. Early reports should briefly describe the initial results of a research topic and will be expedited through peer-review.

    Manuscripts describing studies on cell lines will only be considered if the data compares at least two types of distinct cell lines and the results have general implications on the understanding of the biology of chest tumours. Authors of studies on cell lines must also agree to make freely available to other researchers any of the cells, clones of cells, or DNA or antibodies, etc, that were used in the research reported and that are not available from commercial suppliers.

    Manuscripts should be submitted online at http://ees.elsevier.com/lungcancer and the instructions on this site should be closely followed.

    Journal Insights

    These journal metrics provide authors with extra insight into the journals and help them in their journal selection process when submitting an article for publication.

    JournalMetrics

    Journal Access

    Articles are available from 1985 to the present. Access to abstracts is complimentary. Access to full text is limited to print subscribers. Register or login to:

    Buy a Subscription Now

    Activate Online Access